Injectable microcushions for joint diseases
Learn more
liposome + linker
CloudLi
CloudLi-1 microcushions, based on the versatile CloudLi™ platform, protect cartilage mechanically and modulate inflammation biologically – tackling both osteoarthritis progression and pain, where other treatments fall short.
Today’s treatments leave too many patients behind.
Corticosteroid injections provide only short-term relief and are unsuitable for many patients. Hyaluronic acid has shown inconsistent benefit in clinical studies.
Platelet-rich plasma, while promising in some cases, is inherently variable because its quality depends on each individual patient. As a result, millions of people continue to live with pain and progressive joint degradation despite available options.
Most new approaches target just one side of the disease.
Drug developers often search for a “silver bullet” to block inflammation biologically, while device approaches focus on lubricating the joint to slow cartilage wear.
But osteoarthritis is a dual-driven disease: mechanical erosion and chronic inflammation reinforce each other. Addressing only one pathway has continuously failed to meaningfully change the course of the disease.
CloudLi-1 is being developed to uniquely tackle both disease drivers
Our lipid-based microcushions coat cartilage to reduce friction and prevent damage.
A peptide crosslinker binds liposomes, forming stable CloudLi clusters that sustain lubrication upon injection and deliver local anti-inflammatory action — targeting the mechanical and biological pathways driving OA pain and progression.
Built on the versatile CloudLi™ platform, this technology allows linker selection to tailor asset functionality, such as tissue targeting and more. It can be harnessed as a drug delivery system for local injections or as a standalone asset, such as CloudLi-1.
Our publications
Here’s some of our work in osteoarthritis as the basis of CloudLi™. Earlier publications describe the first generation of our technology, developed as a cartilage-lubricating drug delivery platform and starting point for today’s disease-modifying CloudLi™ micro-cushions.
Our pipeline
CloudLi-1 is our osteoarthritis lead, built on the CloudLi™ platform, expandable to new indications. The platform is tuneable—linker choice enables features beyond anti-inflammation, such as tissue targeting—and it supports drug delivery.
Program | Disease | Discovery“In vivo” lead optimizationIND-enablingClinical |
|---|---|---|
| CloudLi-1 | Osteoarthritis | |
Funding our mission
Eldian Biomed is supported by highly competitive grants and fellowships, including Innosuisse, Bridge PoC, Venture Kick, and the University of Bern Venture Fellowship. We are grateful to these institutions for their early belief in our vision.
Their support not only validates the disruptive potential of CloudLi™ but has been instrumental in transforming our scientific innovation into a tangible therapeutic path for osteoarthritis and beyond.
